TH
protein-codingtyrosine hydroxylase
Gene summary
The protein encoded by this gene is involved in the conversion of tyrosine to dopamine. It is the rate-limiting enzyme in the synthesis of catecholamines, hence plays a key role in the physiology of adrenergic neurons. Mutations in this gene have been associated with autosomal recessive Segawa syndrome. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~7.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0011551
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0100064
Submitter: Natera
Inheritance Pattern: AR
Disease ID:MONDO:0100064
Submitter: ClinGen
The relationship between TH and tyrosine hydroxylase deficiency, an autosomal recessive disorder of tyrosine metabolism, was evaluated using the ClinGen Clinical Validity Framework as of March 8th, 2019. Variants in TH were first reported in humans with this disorder in 1995 (Lüdecke et al, PMID 7814018). Evidence supporting this gene-disease relationship includes case-level data and experimental data. Fourteen unique variants were curated (missense, nonsense, frameshift, intronic, and promoter) in 15 probands from 14 publications (Lüdecke et al, 1995, PMID 7814018; van den Heuvel et al, 1998, PMID 9703425; Janssen et al, 2000, PMID 11281275; Swaans et al, 2000, PMID 11246459; Furukawa et al, 2001, PMID 11160968; Hoffmann et al, 2003, PMID 12891655; Ribasés et al, 2007, PMID 17698383; Verbeek et al, 207, PMID 17696123; Pons et al, 2010, PMID 20198643; Ormazabal et al, 2011, PMID 21465550; Chi et al, 2012, PMID 22264700; Goswami et al, 2017, PMID 28667724; Katus et al, 2017, PMID 29225908; Feng et al, 2018, PMID 30383639). More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The mechanism for disease is biallelic loss of function. This gene-disease relationship is supported by the biochemical function of TH, which catalyzes the conversion of L-tyrosine to L-dopa (Nagatsu et al, 1964, PMID 5836553), functional studies (Fossbakk et al, 2014, PMID 24753243) and the biochemical features and clinical features of mouse models (Kobayashi et al, 1995, PMID 7592982; Korner et al, 2015, PMID 26276013). In summary, TH is definitively associated with TH deficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Aminoacidopathy Gene Curation Expert Panel. This curation includes data collected by Counsyl.
Inheritance Pattern: AR
Disease ID:MONDO:0011551
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0011551
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0100064
Submitter: Myriad Women's Health
Inheritance Pattern: AR
Disease ID:MONDO:0011551
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Biochemical; Neurologic
Intervention: Biochemical
Rationale: The condition can have infantile onset, and treatment (eg, with L-dopa alone or combined with other medications), can be effective, though has not been reported to be universally so
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to TH variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_000360.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 9 | 323 | 5 | 337 | ||
| missense | 2 | 52 | 309 | 12 | 1 | 376 |
| nonsense | 14 | 18 | 32 | |||
| start loss | 1 | 1 | ||||
| frameshift | 24 | 43 | 67 | |||
| splice donor/acceptor (+/-2bp) | 2 | 39 | 1 | 42 | ||
| Total | 42 | 152 | 320 | 335 | 6 | 855 |
Highest pathogenic variant AF is 0.00014401547
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_000351.2 | 13 | MANE Select | |
| Ensembl | ENSP00000325951.4 | 13 | MANE Select | |
| RefSeq | NP_001427464.1 | 13 | Standard | |
| RefSeq | NP_001427465.1 | 11 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| th | Danio rerio | Structure: head Quality: decreased amount abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Folate biosynthesis - Homo sapiens (human)
- Dopaminergic synapse - Homo sapiens (human)
- Amphetamine addiction - Homo sapiens (human)
- Prolactin signaling pathway - Homo sapiens (human)
- Parkinson,s disease - Homo sapiens (human)
Biological Process
- response to hypoxia
- synaptic transmission, dopaminergic
- response to amphetamine
- heart morphogenesis
- dopamine biosynthetic process from tyrosine
Molecular Function
- tyrosine 3-monooxygenase activity
- protein binding
- ferrous iron binding
- ferric iron binding
- amino acid binding
Cellular Component
- nucleus
- cytoplasm
- mitochondrion
- smooth endoplasmic reticulum
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000381178
- Coding exons
- 14
- Length
- 7949
- Individuals with no LoFs
- 125563
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 39
- Defined
- 125602
- p
- 0.000155
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.564 | 321 | 351 | 0.915 | 0.0000246 | 3327 |
| Missense (PolyPhen) | 106 | 142.71 | 0.74276 | 1390 | ||
| Synonymous | -0.191 | 160 | 157 | 1.02 | 0.0000117 | 1093 |
| Loss of Function | 2.42 | 14 | 27.8 | 0.504 | 0.00000146 | 298 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00012 | 0.00012 | rare |
| Latino/Admixed American | 0.00014 | 0.00014 | rare |
| Ashkenazi Jewish | 0.00010 | 0.000099 | rare |
| East Asian | 0.00099 | 0.00098 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000093 | 0.000088 | rare |
| South Asian | 0.000070 | 0.000065 | rare |
| Other | 0.00016 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Plays an important role in the physiology of adrenergic neurons.;
- Disease
- DISEASE: Note=May play a role in the pathogenesis of Parkinson disease (PD). A genome-wide copy number variation analysis has identified a 34 kilobase deletion over the TH gene in a PD patient but not in any controls. {ECO:0000269|PubMed:20809526}.;
Recessive Scores
- pRec
- 0.855
Intolerance Scores
- LoFtool
- 0.0190
- RVIS EVS
- -0.95
- RVIS percentile EVS
- 9.27
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.975
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | High |
| Cancer | Medium | Medium | Medium |